Dermatology Department, Virgen del Rocío University Hospitals, Seville, Spain.
Dermatol Ther. 2013 Sep-Oct;26(5):415-8. doi: 10.1111/dth.12014. Epub 2013 Mar 13.
Lupus erythematosus panniculitis (LEP) or lupus profundus (LP) is a clinical variant of lupus eryhematosus that involves the deep dermis and the subcutaneous fat and is associated with tender subcutaneous nodules or plaques, with occasional ulceration, atrophy, and scarring. The management of this entity can be difficult because of the lack of response to conventional treatments, such as systemic steroids and antimalarials. The two patients of this study presented LP refractory to several therapies that demonstrated a remarkable improve to the infusion of the anti-CD20 monoclonal antibody, rituximab at a dosage of 375 mg/m²/week. After the first infusion, painful lesions had resolved without the appearance of new lesions. Rituximab may be an effective treatment for patients with LP when other therapies are ineffective. To date, there is only one case report of LEP treated with rituximab in the literature.
狼疮性脂膜炎（LEP）或深部狼疮（LP）是一种累及真皮深层和皮下脂肪的红斑狼疮临床变异型，其特征为触痛性皮下结节或斑块，偶有溃疡、萎缩和瘢痕形成。由于对常规治疗（如全身类固醇和抗疟药）反应不佳，该疾病的治疗可能较为困难。本研究中的两名患者 LP 对几种治疗方法均无反应，但抗 CD20 单克隆抗体利妥昔单抗（剂量为 375mg/m²/周）输注后显著改善。首次输注后，疼痛性病变消退，且无新病变出现。当其他治疗方法无效时，利妥昔单抗可能是 LP 患者的一种有效治疗方法。迄今为止，文献中仅有一例 LEP 用利妥昔单抗治疗的病例报告。
